Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Total Debt (2018 - 2023)

X4 Pharmaceuticals (XFOR) has disclosed Total Debt for 5 consecutive years, with $764000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Total Debt fell 91.12% year-over-year to $764000.0, compared with a TTM value of $764000.0 through Jun 2023, down 91.12%, and an annual FY2022 reading of $1.3 million, up 65.41% over the prior year.
  • Total Debt was $764000.0 for Q2 2023 at X4 Pharmaceuticals, up from $554000.0 in the prior quarter.
  • Across five years, Total Debt topped out at $26.3 million in Q2 2019 and bottomed at $554000.0 in Q1 2023.
  • Average Total Debt over 4 years is $6.2 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Total Debt surged 2009.81% in 2022, then crashed 91.12% in 2023.
  • Year by year, Total Debt stood at $26.3 million in 2019, then crashed by 96.98% to $795000.0 in 2021, then surged by 65.41% to $1.3 million in 2022, then plummeted by 41.9% to $764000.0 in 2023.
  • Business Quant data shows Total Debt for XFOR at $764000.0 in Q2 2023, $554000.0 in Q1 2023, and $1.3 million in Q4 2022.